An observational study in Renal Insufficiency, Chronic, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 4 sites in France. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 238 studies in Renal Insufficiency, Chronic with a site in France — 55 open to participants now, 69 under way, 17 of them phase 3. Renal Insufficiency, Chronic · France.
Among the 238 studies in Renal Insufficiency, Chronic with a site in France, this one is the 6th largest by planned enrollment of the 73 observational ones that give a count, is one of 13 that started in 2019, is one of 73 observational ones, reaches primary completion later than 32 of the 68 other live ones, and was the 99th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →55 of the 238 studies in Renal Insufficiency, Chronic with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18+ · Healthy volunteers
AstraZeneca · Sites in France, United States, Argentina and 24 more countries
Ages 18–99
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–80
AstraZeneca · Sites in France, United States, Argentina and 34 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in France, United States, China and 5 more countries
Ages 2–18
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
238 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 31 · Phase 3 62 · Phase 4 9
First in 2003; this study’s year is marked. 13 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,375 is above the median of 213 across 835 observational studies indexed under Renal Insufficiency, Chronic.
Median enrollment 170 across the 165 interventional studies, 165 across the 73 observational. Of the 147 that completed or were terminated, 50 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 238 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.
Centre Hospitalier Universitaire de Nīmes has 3 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
20 of the studies in Renal Insufficiency, Chronic with a site in France that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT03969329Phase 3AmgenA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | 2027-06-30 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06692231Centre Hospitalier de VichyImpact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients | 2026-11-30 |
Add all 20 to your calendar (.ics) → With an account.
Among the 238 studies in Renal Insufficiency, Chronic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. To verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the French High Authority of Health (HAS), laboratory data will be compared with those of patients seen by nephrologists in the department.
Persons with >= stage 4 chronic kidney disease and residing in the Gard department of France.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Persons with stage \>=4 chronic kidney disease.
The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (raw number)
Time frame: from baseline (day 0) to 12 months
The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (%)
Time frame: from baseline (day 0) to 12 months
The percentage of patients with CKD stage >= 4 correctly reported by participating nephrologists
Time frame: from baseline (day 0) to 12 months
For each nephrologist participating in the study, the % of patients with stage >=4 chronic kidney disease who are correctly declared
Time frame: from baseline (day 0) to 12 months
The % of patients with chronic kidney disease stage > = 4 in the Gard according to laboratory data and who are not seen by a nephrologist
Time frame: from baseline (day 0) to 12 months
Started Jan 2019 (actual). Primary completion is estimated for Dec 2027, 107 months after the start.
Of 276 non-industry observational studies under Renal Insufficiency, Chronic, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 192. This study's planned 107 months is above that.
Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Dec 2025 → Dec 2027 and completion Dec 2025 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Centre Hospitalier Universitaire de Nīmes →